Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting NCT07777744

Severe Complications During Ventricular Tachycardia or Premature Ventricular Complex Ablation

Severe Complications During Ventricular Tachycardia or Premature Ventricular Complex Ablation — Recruiting • Cardiology / Cardiovascular • NCT07777744.

📅 20 Aug 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT07777744
Sponsor
University Hospital, Basel, Switzerland
Start
2024-07-01
ClinicaliQ Trial Snapshot
  • Severe Complications During Ventricular Tachycardia or Premature Ventricular Complex Ablation — Recruiting • Cardiology / Cardiovascular • NCT07777744.
  • What is being tested: This observational study characterizes severe complications occurring during ventricular tachycardia (VT) and premature ventricular complex (PVC) ablation procedures, collecting retrospective patient-level data on complication features, procedural factors, and clinical management strategies.
  • Patient eligibility overview: The study includes patients who have experienced severe complications during VT/PVC ablation procedures; specific inclusion criteria relate to complication severity and procedure type rather than baseline patient demographics.
Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The investigators aim to characterize patients presenting with a severe ventricular tachycardia (VT) and premature ventricular complex (PVC)-ablation-related complication including patient characteristics, procedural details and subsequent management of the complication by gathering existing patient-level data.

Eligibility Snapshot
  • : * Centers : Centers participating in the present collaborative study group. Invitation to participate will be based either upon personal referral of one of the investigator, previous collaboration or based on a meta-analytic review of the literature published on the subject within the past 20 years. * Patients: Females and males of >18 years undergoing any type of VT/PVC ablation. While we will accept redo-procedure we will ask for a unique patient-identifier to link procedures belonging to the same patients together. * Interventions: VT/PVC ablation (first intervention or re-do) as routinely performed by the participating centers * Outcomes: Severe complications, defined as hemodynamic instability requiring mechanical intensive-care management, tamponade, stroke, cardiac arrest, myocardial infarction, phrenic nerve palsies, major bleeding requiring transfusion, vascular or cardiac complication requiring surgery, procedure-related death. * Setting: Observational cohort studies, registries, retrospective cohort studies. Data stemming from RCTs (Randomized controlled trials) will not be collected as they likely do not represent a "real-life" setting. * Length of follow-up: Peri-procedural complications * Years considered: Not limited to a specific time-frame, but to reflect common ablation practices, we will focus on data from the 20 past years. * Number of patients provided : No lower limit…

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity
Cardiology / Cardiovascular · 07 May 2026
Semaglutide is recommended for adults with established cardiovascular disease and overweight/obesity to reduce major adverse cardiovascular events – consider prescribing as part…
View guideline →
Guideline
2022 ESC Guidelines for the Management of Patients with Ventricular Arrhythmias
Cardiology / Cardiovascular · 30 Mar 2026
Covers risk stratification for sudden cardiac death and indications for ICD implantation • Provides management recommendations for ventricular tachycardia and ventricular fibrillation…
View guideline →
Clinical Brief
Weight-loss jabs will be offered on NHS for people at risk of further heart attacks
Cardiology / Cardiovascular · BBC Health · 31 Mar 2026
GLP-1 receptor agonists (weight-loss jabs) will now be offered on NHS to over 1 million people in England at high cardiovascular risk,…
View brief →
Guideline
Artificial intelligence (AI)-assisted echocardiography analysis and reporting to support the diagnosis and monitoring of heart failure: early-use assessment
Cardiology / Cardiovascular · 19 May 2026
AI-assisted echocardiography can support faster preliminary analysis and reporting of echo images in heart failure patients, potentially reducing reporting delays and improving…
View guideline →
Guideline
2024 ESC Guidelines for the Management of Atrial Fibrillation
Cardiology / Cardiovascular · 30 Mar 2026
Covers AF classification, stroke risk assessment (CHA2DS2-VASc), and bleeding risk (HAS-BLED) • Provides recommendations for rate vs rhythm control strategies • Addresses…
View guideline →
Guideline
Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy
Cardiology / Cardiovascular · 30 Jul 2026
Patient selection: Consider aficamten for symptomatic obstructive hypertrophic cardiomyopathy patients who remain symptomatic despite optimised standard therapy (beta-blockers, non-dihydropyridine calcium channel blockers,…
View guideline →